Skip to content
BHP

Survodutide

BI 456906 · Dual GLP-1/glucagon agonist

Reviewed by the BestHealingPeptides Editorial Team ·

On this page

A Boehringer Ingelheim dual GLP-1/glucagon receptor agonist, licensed from Zealand Pharma — a two-receptor mechanism intermediate between semaglutide's single GLP-1R agonism and retatrutide's triple GLP-1R/GIPR/glucagon-R agonism. The GLP-1 + glucagon combination pairs appetite suppression (GLP-1R) with proposed energy-expenditure enhancement (glucagon-R) without the additional GIPR dimension of retatrutide. The Phase III SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD trials were published in 2026; survodutide remains investigational and is not approved in any jurisdiction (Zealand Pharma company announcement, 1 October 2026).

Mechanism of action

Survodutide (Boehringer Ingelheim development code BI 456906, licensed from Zealand Pharma) is a dual GLP-1 receptor and glucagon receptor agonist — engaging both incretin (GLP-1R) and counter-regulatory (glucagon-R) pharmacology in a single molecule. The two-receptor mechanism is architecturally intermediate between semaglutide (GLP-1R monoagonist), tirzepatide (GLP-1R/GIPR dual agonist), and retatrutide (GLP-1R/GIPR/glucagon-R triple agonist). Survodutide's specific innovation is the GLP-1 + glucagon combination without GIPR involvement.

The pharmacological rationale for combining GLP-1R and glucagon-R agonism parallels retatrutide's rationale: GLP-1R engagement drives appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying; glucagon-R engagement is proposed to raise energy expenditure through hepatic and adipose lipolysis and fatty-acid oxidation. The glucose-dependence of GLP-1-driven insulin secretion is the mechanistic argument offered for why the glucagon component need not produce significant hyperglycaemia — the same argument made for the glucagon component of retatrutide.

The absence of GIPR agonism distinguishes survodutide from tirzepatide and retatrutide. GIPR contributes to insulinotropic effects and modulates lipogenesis; the pharmacological importance of GIPR co-agonism versus GLP-1/glucagon-only combination is an open comparative question that head-to-head trials would clarify. In SYNCHRONIZE-1 (NEJM 2026; 725 adults with obesity without diabetes, 76 weeks), mean weight change by the treatment-regimen estimand was −12.2% (3.6 mg) and −13.0% (6.0 mg) versus −5.4% with placebo. There has been no head-to-head trial of survodutide against tirzepatide, so the two should not be ranked from separate trials.

Survodutide has received particular attention for MASLD (metabolic-associated steatotic liver disease, formerly NAFLD/NASH). The glucagon-R agonism component is proposed to reduce hepatic fat through direct effects on hepatocyte lipid handling. Survodutide's Phase II MASH trial (Sanyal et al., NEJM 2024; 293 adults, 48 weeks) reported improvement in MASH without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg) and 43% (6.0 mg) of participants versus 14% with placebo. In the Phase III SYNCHRONIZE-MASLD trial (Kaplan et al., Nature Medicine 2026; 216 adults, survodutide 6.0 mg, 48 weeks), 84.2% of survodutide-treated participants versus 24.3% of placebo-treated participants had at least a 30% reduction in liver fat (efficacy estimand; 68.5% versus 28.6% by the treatment-regimen estimand).

Downstream of receptor activation, survodutide produces the integrated GLP-1 + glucagon phenotype: appetite suppression + energy expenditure elevation + direct hepatic lipid mobilisation. This pharmacological footprint distinguishes it from GLP-1 monoagonists (appetite suppression only) and from GLP-1/GIPR dual agonists (appetite suppression + modified adipose metabolism without direct hepatic lipid targeting).

In the Phase II MASH trial, improvement in MASH without worsening of fibrosis occurred in 43-62% of survodutide-treated participants versus 14% with placebo (Sanyal et al., NEJM 2024), and in the Phase III SYNCHRONIZE-MASLD trial 84.2% versus 24.3% had at least a 30% reduction in liver fat (efficacy estimand; Nature Medicine 2026). Survodutide remains investigational: Zealand Pharma describes it as an agent that has not been approved for use, and the dedicated LIVERAGE MASH trials are still ongoing.

— Notable finding

Research history

Survodutide (BI 456906) is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer Ingelheim solely responsible for its global development and commercialisation (Zealand Pharma company announcement, 1 October 2026).

Phase II results were published in 2024. The obesity trial (le Roux et al., Lancet Diabetes Endocrinol 2024; 387 adults, 46 weeks) reported mean weight change of −6.2%, −12.5%, −13.2% and −14.9% at 0.6, 2.4, 3.6 and 4.8 mg versus −2.8% with placebo (planned-treatment analysis). The MASH trial (Sanyal et al., NEJM 2024) reported improvement in MASH without worsening of fibrosis in 47%, 62% and 43% of participants at 2.4, 4.8 and 6.0 mg versus 14% with placebo.

The Phase III SYNCHRONIZE-1 (obesity, NEJM 2026), SYNCHRONIZE-2 (obesity with type 2 diabetes, NEJM 2026) and SYNCHRONIZE-MASLD (Nature Medicine 2026) trials have been published. Per ClinicalTrials.gov, the SYNCHRONIZE cardiovascular safety trial (NCT06077864) is listed as completed, and the LIVERAGE MASH trials (NCT06632444 and NCT06632457) are recruiting.

As of 29 October 2026, survodutide is described by Zealand Pharma as an investigational agent that has not been approved for use. It is not licensed in any jurisdiction.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Reported Survodutide research-model dose ranges
ModelRouteReported rangeNote
Phase II obesity (Le Roux 2024)Subcutaneous injection0.6, 2.4, 3.6 or 4.8 mg weeklyPhase II 46-week dose-finding trial (20 weeks dose escalation, 26 weeks maintenance).
Phase II MASH (Sanyal 2024)Subcutaneous injection2.4, 4.8 or 6.0 mg weekly48-week trial: 24-week rapid dose escalation followed by 24-week maintenance.
Phase III SYNCHRONIZE-1 and -2 (2026)Subcutaneous injectionAdjusted up to 3.6 mg or 6.0 mg weekly76-week trials. SYNCHRONIZE-MASLD used 6.0 mg weekly for 48 weeks.
Not for research-chemical useNot applicableNot applicableClinical-development peptide; not appropriate for research-chemical-community protocols.
Ranges reported in pre-clinical literature. For laboratory and research use only.

Reconstitution & storage

Summarised studies

Summarised research studies
YearModelOutcomeCitationSource
2024Adults with obesity, Phase II RCTMean weight change up to −14.9% (4.8 mg) versus −2.8% with placebo at 46 weeks (planned-treatment analysis)Le Roux CW, Steen O, Lucas KJ, et al. Lancet Diabetes Endocrinol. 2024;12(3):162-173PMID 38330987
2024Adults with MASH, Phase II RCTMASH improvement without fibrosis worsening in 43-62% (survodutide) versus 14% (placebo) at 48 weeksSanyal AJ, Bedossa P, Fraessdorf M, et al. N Engl J Med. 2024;391(4):311-319PMID 38847460
2026Adults with obesity without diabetes, Phase III RCT−12.2% (3.6 mg) and −13.0% (6.0 mg) versus −5.4% with placebo at 76 weeks (treatment-regimen estimand)le Roux CW, et al. N Engl J Med. 2026 (SYNCHRONIZE-1; NCT06066515)PMID 42253238
2026Adults with obesity and type 2 diabetes, Phase III RCT−8.2% (3.6 mg) and −9.8% (6.0 mg) versus −3.9% with placebo at 76 weeks (treatment-regimen estimand)Wharton S, et al. N Engl J Med. 2026 (SYNCHRONIZE-2; NCT06066528)PMID 42820639
2026Adults with obesity and at-risk MASLD, Phase III RCTAt least 30% liver-fat reduction in 84.2% versus 24.3% (efficacy estimand) at 48 weeksKaplan LM, et al. Nat Med. 2026PMID 42252333

Survodutide for adults with obesity (Phase 2 trial)

Le Roux CW, Steen O, Lucas KJ, et al. Lancet Diabetes Endocrinol. 2024;12(3):162-173 · 2024 · PMID 38330987

Phase II 46-week dose-finding trial of survodutide 0.6, 2.4, 3.6 and 4.8 mg weekly versus placebo in 387 adults without diabetes (BMI 27 or higher). By planned-treatment analysis, mean weight change was −6.2%, −12.5%, −13.2% and −14.9% respectively versus −2.8% with placebo. Adverse events were primarily gastrointestinal.

PubMed

Survodutide for treatment of metabolic dysfunction-associated steatohepatitis (Phase 2 trial)

Sanyal AJ, Bedossa P, Fraessdorf M, et al. N Engl J Med. 2024;391(4):311-319 · 2024 · PMID 38847460

Phase II 48-week trial in adults with biopsy-confirmed MASH and fibrosis stage F1-F3 given survodutide 2.4, 4.8 or 6.0 mg weekly or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47%, 62% and 43% of participants respectively versus 14% with placebo; a decrease in liver fat of at least 30% occurred in 63%, 67% and 57% versus 14%. The authors concluded the results warranted further investigation in phase 3 trials.

PubMed

Survodutide once weekly for the treatment of adults with obesity (SYNCHRONIZE-1)

le Roux CW, et al. N Engl J Med. 2026 (SYNCHRONIZE-1; NCT06066515) · 2026 · PMID 42253238

Phase III double-blind trial of survodutide up to 3.6 mg or 6.0 mg weekly versus placebo in 725 adults with obesity and no diabetes over 76 weeks. By the treatment-regimen estimand, mean weight change was −12.2% (3.6 mg), −13.0% (6.0 mg) and −5.4% (placebo); weight reduction of at least 5% occurred in 72.6%, 71.9% and 46.3%. Gastrointestinal adverse events occurred in 80.9%, 89.7% and 47.9%.

PubMed

Survodutide once weekly in adults with obesity and type 2 diabetes (SYNCHRONIZE-2)

Wharton S, et al. N Engl J Med. 2026 (SYNCHRONIZE-2; NCT06066528) · 2026 · PMID 42820639

Phase III double-blind trial of survodutide 3.6 mg or 6.0 mg weekly versus placebo in 752 adults with type 2 diabetes and BMI 27 or higher over 76 weeks. By the treatment-regimen estimand, mean weight change was −8.2% (3.6 mg), −9.8% (6.0 mg) and −3.9% (placebo); HbA1c changed by −0.9, −0.8 and −0.2 percentage points from a baseline of 7.4%. Boehringer Ingelheim's efficacy-estimand figure of up to 13.1% versus 3.1% is a company-reported number (Zealand Pharma announcement, 1 October 2026).

PubMed

Survodutide in adults with obesity and MASLD (SYNCHRONIZE-MASLD)

Kaplan LM, et al. Nat Med. 2026 · 2026 · PMID 42252333

Phase III double-blind trial of survodutide 6.0 mg weekly (n=146) versus placebo (n=70) for 48 weeks in adults with obesity and at-risk MASLD. A reduction of at least 30% in MRI-PDFF liver fat occurred in 84.2% versus 24.3% (efficacy estimand) and 68.5% versus 28.6% (treatment-regimen estimand). Mean weight change was −12.2% versus −1.0% (efficacy estimand). The authors noted the short duration and limited geographic reach (United States and Spain).

PubMed

Safety profile

In the published trials the most common adverse events were gastrointestinal. In SYNCHRONIZE-1 (NEJM 2026) gastrointestinal adverse events occurred in 80.9% (3.6 mg) and 89.7% (6.0 mg) of participants versus 47.9% with placebo, and in SYNCHRONIZE-2 (NEJM 2026) in 72.8% and 77.7% versus 38.6%; the abstracts describe them as typically mild to moderate. In the Phase II MASH trial, nausea (66% vs 23%), diarrhoea (49% vs 23%) and vomiting (41% vs 4%) were more frequent with survodutide than with placebo, and serious adverse events occurred in 8% with survodutide and 7% with placebo (Sanyal et al., NEJM 2024). In the Phase II obesity trial adverse events occurred in 91% of survodutide recipients and 75% of placebo recipients, primarily gastrointestinal (le Roux et al., 2024).

Survodutide is not approved, so there is no UK Summary of Product Characteristics and no licensed contraindication or warning list. Other GLP-1 receptor agonist medicines carry labelled warnings, but this reference does not extend those to survodutide. Cardiovascular safety is the subject of a dedicated trial (SYNCHRONIZE-CVOT, NCT06077864), which ClinicalTrials.gov lists as completed; Boehringer Ingelheim had said it expected to present the results later in 2026 (Zealand Pharma announcement, 1 October 2026), and this reference has not found them.

Reported contraindications & cautions

  • Not a licensed medicine — there is no UK Summary of Product Characteristics and no formal contraindication list
  • Trial eligibility criteria are set by each trial protocol and are not a statement of medical contraindications

Known formulation interactions

  • No approved product information exists, so no interaction list can be cited. Anyone taking survodutide in a clinical trial should follow the trial team's advice on other medicines.

UK regulatory status

Survodutide is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction as of 29 October 2026; Zealand Pharma (1 October 2026) describes it as an investigational agent that has not been approved for use. Boehringer Ingelheim's Phase III SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD trials have been published; SYNCHRONIZE-CVOT results have not, and the LIVERAGE trials are ongoing. This reference did not find an announced regulatory submission to the MHRA, EMA or US FDA, and makes no claim about when one might be made.

Without a marketing authorisation, survodutide is not available as a medicine in the UK. Supply or administration to people outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012. Unregulated supply of clinical-development peptides carries substantial safety and regulatory risk.

Survodutide is not named on the WADA Prohibited List; WADA's S0 category covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use, so athletes should check its status with their anti-doping organisation. Not a controlled drug under the Misuse of Drugs Act 1971. For animal research under ASPA, survodutide work in vertebrates requires standard project and personal licences.

Frequently asked questions

What is survodutide?
Survodutide (BI 456906) is an investigational dual GLP-1 receptor and glucagon receptor agonist developed by Boehringer Ingelheim and licensed from Zealand Pharma. It combines GLP-1R activation (appetite suppression) with glucagon-receptor activation (proposed to raise energy expenditure) in a once-weekly subcutaneous injection in the clinical trials. It has not been approved for use anywhere.
How does survodutide compare with retatrutide?
Both engage the glucagon receptor for the energy-expenditure component. Survodutide is dual-agonist (GLP-1R + glucagon-R); retatrutide is triple-agonist (adds GIPR). In separate Phase III obesity trials without diabetes, retatrutide produced −25.0% at 12 mg over 80 weeks versus −3.9% with placebo (TRIUMPH-1, NEJM 2026), and survodutide produced −13.0% at 6.0 mg over 76 weeks versus −5.4% with placebo (SYNCHRONIZE-1, NEJM 2026). These are different trials and not a head-to-head comparison.
Why is survodutide notable for MASH/MASLD?
The glucagon-receptor component is proposed to act directly on the liver to reduce hepatic fat. In its Phase II MASH trial, improvement in MASH without worsening of fibrosis occurred in 43-62% of survodutide-treated participants versus 14% with placebo (Sanyal et al., NEJM 2024). In the Phase III SYNCHRONIZE-MASLD trial, 84.2% versus 24.3% had at least a 30% reduction in liver fat (efficacy estimand; Nature Medicine 2026). The LIVERAGE MASH trials are ongoing.
Is survodutide available in the UK?
No — survodutide is not MHRA-licensed and is not approved in any jurisdiction (Zealand Pharma, 1 October 2026: an investigational agent that has not been approved for use). This reference found no announced regulatory submission and does not predict when, or whether, it might be licensed.
How does the glucagon component work without causing hyperglycaemia?
The strict glucose-dependence of GLP-1R-driven insulin secretion provides a counter-balancing mechanism. When blood glucose rises (whether from meal intake or glucagon-driven hepatic glucose mobilisation), GLP-1R activation increases insulin secretion; when blood glucose is normal, GLP-1R-driven insulin secretion is minimal. This glucose-dependent counter-balance is the mechanism proposed to limit hyperglycaemia from the glucagon-agonism component. In SYNCHRONIZE-2 (adults with type 2 diabetes), HbA1c fell by 0.8-0.9 percentage points with survodutide versus 0.2 with placebo (NEJM 2026).
Is survodutide prohibited in sport?
Survodutide is not named on the WADA Prohibited List. WADA's S0 category covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use, so athletes should check its status with their anti-doping organisation.
Which Phase III trials of survodutide have been published?
SYNCHRONIZE-1 (obesity without diabetes; NEJM 2026) and SYNCHRONIZE-2 (obesity with type 2 diabetes; NEJM 2026) both ran for 76 weeks with 3.6 mg and 6.0 mg weekly doses, and SYNCHRONIZE-MASLD (Nature Medicine 2026) tested 6.0 mg for 48 weeks. By the treatment-regimen estimand, weight change was −12.2% (3.6 mg) and −13.0% (6.0 mg) versus −5.4% with placebo in SYNCHRONIZE-1, and −8.2% and −9.8% versus −3.9% in SYNCHRONIZE-2.

References

  1. Survodutide for adults with obesity (Phase 2 trial). Le Roux CW, Steen O, Lucas KJ, et al. Lancet Diabetes Endocrinol. 2024;12(3):162-173 (2024). PMID 38330987
  2. Survodutide for treatment of metabolic dysfunction-associated steatohepatitis (Phase 2 trial). Sanyal AJ, Bedossa P, Fraessdorf M, et al. N Engl J Med. 2024;391(4):311-319 (2024). PMID 38847460
  3. Survodutide once weekly for the treatment of adults with obesity (SYNCHRONIZE-1). le Roux CW, et al. N Engl J Med. 2026 (SYNCHRONIZE-1; NCT06066515) (2026). PMID 42253238
  4. Survodutide once weekly in adults with obesity and type 2 diabetes (SYNCHRONIZE-2). Wharton S, et al. N Engl J Med. 2026 (SYNCHRONIZE-2; NCT06066528) (2026). PMID 42820639
  5. Survodutide in adults with obesity and MASLD (SYNCHRONIZE-MASLD). Kaplan LM, et al. Nat Med. 2026 (2026). PMID 42252333
  6. Le Roux et al. 2024 — Phase II obesity (PMID 38330987)
  7. Sanyal et al. 2024 — Phase II MASH (PMID 38847460)
  8. le Roux et al. 2026 — SYNCHRONIZE-1, NEJM (PMID 42253238)
  9. Wharton et al. 2026 — SYNCHRONIZE-2, NEJM (PMID 42820639)
  10. Kaplan et al. 2026 — SYNCHRONIZE-MASLD, Nat Med (PMID 42252333)
  11. PubChem — survodutide (CID 171378821)
  12. ClinicalTrials.gov — SYNCHRONIZE-CVOT (NCT06077864)
  13. ClinicalTrials.gov — LIVERAGE (NCT06632444)
  14. MHRA — UK medicines regulator

Where to source Survodutide for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.

Related peptides